Acute visual loss after ipilimumab treatment for metastatic melanoma

Acute visual loss after ipilimumab treatment for metastatic melanoma

Background Ipilimumab, a humanized CLTA-4 antibody is a standard therapy in the treatment of advanced melanoma. While ipilimumab provides an overall survival benefit to patients, it can be associated with immune related adverse events (IrAEs).Case presentation Here we describe a patient treated with...

Full description

Bibliographic Details
Main Authors: Melissa A. Wilson, Kelly Guld, Steven Galetta, Ryan D. Walsh, Julia Kharlip, Madhura Tamhankar, Suzanne McGettigan, Lynn M. Schuchter, Leslie A. Fecher
Format: Article
Language:English
Published: BMJ Publishing Group 2016-11-01
Series:Journal for ImmunoTherapy of Cancer
Online Access:https://jitc.bmj.com/content/4/1/66.full

Internet

https://jitc.bmj.com/content/4/1/66.full

Similar Items